erlotinib hydrochloride has been researched along with Carcinoma, Thymic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anile, M; Bellissimo, T; Blandino, G; De Angelis, L; Diso, D; Facciolo, F; Fazi, F; Gallo, E; Ganci, F; Giangaspero, F; Marino, M; Masciarelli, S; Pescarmona, E; Petrozza, V; Pulito, C; Sacconi, A; Tito, C; Venuta, F | 1 |
| Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D | 1 |
| Koshiishi, H; Takahashi, E; Takahashi, M | 1 |
3 other study(ies) available for erlotinib hydrochloride and Carcinoma, Thymic
| Article | Year |
|---|---|
Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epigenesis, Genetic; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasms, Glandular and Epithelial; RNA, Messenger; Thymoma; Thymus Neoplasms | 2017 |
Response of malignant thymoma to erlotinib.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma | 2008 |
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].
Topics: Adult; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Recurrence; Thymoma; Thymus Neoplasms | 2011 |